PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(12): e15106.
Published online 2010 December 3. doi:  10.1371/journal.pone.0015106
PMCID: PMC2997079

Deficiency of Vasodilator-Stimulated Phosphoprotein (VASP) Increases Blood-Brain-Barrier Damage and Edema Formation after Ischemic Stroke in Mice

Sven G. Meuth, Editor

Abstract

Background

Stroke-induced brain edema formation is a frequent cause of secondary infarct growth and deterioration of neurological function. The molecular mechanisms underlying edema formation after stroke are largely unknown. Vasodilator-stimulated phosphoprotein (VASP) is an important regulator of actin dynamics and stabilizes endothelial barriers through interaction with cell-cell contacts and focal adhesion sites. Hypoxia has been shown to foster vascular leakage by downregulation of VASP in vitro but the significance of VASP for regulating vascular permeability in the hypoxic brain in vivo awaits clarification.

Methodology/Principal Findings

Focal cerebral ischemia was induced in Vasp−/− mice and wild-type (WT) littermates by transient middle cerebral artery occlusion (tMCAO). Evan's Blue tracer was applied to visualize the extent of blood-brain-barrier (BBB) damage. Brain edema formation and infarct volumes were calculated from 2,3,5-triphenyltetrazolium chloride (TTC)-stained brain slices. Both mouse groups were carefully controlled for anatomical and physiological parameters relevant for edema formation and stroke outcome. BBB damage (p<0.05) and edema volumes (1.7 mm3±0.5 mm3 versus 0.8 mm3±0.4 mm3; p<0.0001) were significantly enhanced in Vasp−/− mice compared to controls on day 1 after tMCAO. This was accompanied by a significant increase in infarct size (56.1 mm3±17.3 mm3 versus 39.3 mm3±10.7 mm3, respectively; p<0.01) and a non significant trend (p>0.05) towards worse neurological outcomes.

Conclusion

Our study identifies VASP as critical regulator of BBB maintenance during acute ischemic stroke. Therapeutic modulation of VASP or VASP-dependent signalling pathways could become a novel strategy to combat excessive edema formation in ischemic brain damage.

Introduction

Disruption of the blood-brain barrier (BBB) and successive edema formation are pathological hallmarks of many neurological diseases and can dramatically deteriorate clinical symptoms especially in patients with ischemic stroke [1], [2]. So far no medication, e. g. steroids or hyperosmolaric solutions, has proven to effectively reduce brain edema in acute stroke [3][5] and the molecular mechanisms underlying edema formation are largely unknown.

The vascular endothelium controls the transition of fluids and cells between blood vessels and the interstitium of most organs including the brain [6]. Efficient barrier function requires stable cell-cell- and cell-matrix-interactions and paracellular permeability is regulated by a complex interplay of transmembrane adhesion molecules, tight junctions and cytoskeletal proteins [7][10]. Impairment of any of these interactions can increase endothelial leakage and result in excessive edema formation [9]. Tight junctions represent the most apical of these cell-cell contacts and are of major importance for sealing vascular barriers. While earlier studies mainly focused on the relevance of transmembrane adhesion molecules for tight junction functionality, there is a growing body of evidence pointing towards a critical role of actin cytoskeleton dynamics in modulating the permeability of the BBB [11] and other endothelia [12], [13].

Vasodilator-stimulated phosphoprotein (VASP) is the founding member of the Enabled/vasodilator-stimulated phosphoprotein (Ena/VASP) protein family [14]. In mammals, this family comprises three molecules: mammalian Ena (Mena), VASP, and Ena/VASP-like (EVL). Ena/VASP proteins are important mediators in actin cytoskeleton control and participate in a variety of actin-based processes such as cell-adhesion, -spreading, and -shape change [14]. Only recently the fundamental role of VASP for maintaining endothelial barrier functions has been established. Several in vitro studies verified the expression of VASP at endothelial cell-cell and cell-matrix contacs in different vascular beds [15][19]. Moreover, VASP was shown to initiate perijunctional actin filament assembly thereby stabilizing cell-cell contacts and decreasing endothelial permeability [18]. Accordingly, increased vascular leakage was observed in the inflamed skin of Vasp−/− mice [18] and mice deficient in Mena, Vasp, and EVL develop spontaneous and generalized edema due to severe vessel texture defects [20]. Although VASP is expressed in primary brain capillary endothelial cells (BCECs) [21], little is known about the significance of VASP for regulating vascular permeability in the central nervous system (CNS) especially under pathological conditions in vivo.

We here show that BBB leakage and edema formation are increased in Vasp−/− mice in a model of brain ischemia/reperfusion(I/R)-injury.

Results

Systemic blood pressure, cerebral blood flow and the brain vasculature are unchanged in Vasp−/− mice

First of all we collected critical physiological and anatomical parameters that could possibly influence stroke outcome and edema formation in genetically altered Vasp−/− mice. A complete Circle of Willis was identified in Vasp−/− and Vasp+/+ mice upon macroscopic assessment and the distribution of the middle cerebral artery (MCA) trunk and branches appeared to be identical (Figure 1A, left panel). Collateralisation via the posterior communicating arteries (PComAs) can affect the susceptibility for brain ischemia in transgenic mice [22]. We therefore assessed the development of PComAs in Vasp−/− mice and littermate controls using a quantitative score [23]. No differences in PComAs scores were found between the both groups (1.9±0.6 versus 1.7±0.6; p>0.05) (Figure 1A, right panel).

Figure 1
Vasp deficiency does not alter anatomical and physiological parameters relevant for stroke outcome.

In the present study tMCAO was used to induce focal brain ischemia. After advancing the filament to the origin of the MCA the decrease in regional cerebral blood flow (rCBF) was similar between WT mice and Vasp−/− mice (17.7%±3.2% versus 18.7%±4.0%; p>0.05) (Figure 1B). Ten minutes after removal of the filament (reperfusion) rCBF in the MCA territory was reconstituted to >60% of baseline levels and again did not significantly differ between the two mouse groups (62.7%±10.4% versus 60.3%±8.3%; p>0.05) (Figure 1B). These findings exclude preformed alterations in rCBF related to the Vasp−/− genotype and prove that MCA occlusion and reperfusion were sufficient in our model.

Changes in arterial blood pressure can directly influence final stroke sizes and the magnitude of BBB disruption [24]. We therefore compared systemic blood pressure and heart rate between the two groups. Again, no significant differences were observed (systolic blood pressure: 115 mm Hg ±9 mm Hg versus 104 mm Hg ±15 mm Hg; diastolic blood pressure 73 mm Hg ±8 mm Hg versus 70 mm Hg ±9 mm Hg; heart rate: 405 min−1 ±31 min−1 versus 487 min−1 ±11 min−1; p>0.05) (Figure 1C).

Vasp deficiency increases infarct size, blood-brain-barrier damage and edema formation after ischemic stroke

We next subjected Vasp−/− mice to tMCAO and, after 24 h, assessed infarct volumes by staining brain sections with 2,3,5-triphenyltetrazolium chloride (TTC) (Figure 2A, upper panel). Infarct volumes were significantly larger, by approximately 45%, in Vasp-deficient mice than in WT controls (56.1 mm3±17.3 mm3 versus 39.3 mm3±10.7 mm3, respectively; p<0.001) (Figure 2A, lower panel). Although mice without Vasp tended to develop more severe neurological deficits after stroke, the difference was not statistically significant (Bederson score: 1.8±0.9 versus 1.5±0.5, respectively; p>0.05) (Figure 2B, upper panel). In line with these results, mortality rates were similar in both groups (p>0.05) (Figure 2B, lower panel). Thus, our observations corroborate previous reports on a poor correlation between infarct size and neurological outcome in rodents [25][27].

Figure 2
Vasp deficiency increases infarct volumes, BBB damage and edema formation after ischemic stroke.

Next we sought to elucidate the underlying mechanisms of this VASP-specific stroke protection. Increased edema formation was recently reported in the inflamed skin of Vasp−/− mice [18] and hypoxia has been shown to foster vascular leakage by downregulation of VASP in vitro [28]. Therefore, we injected mice the vascular tracer Evan's Blue to investigate whether VASP is also involved in stroke-induced BBB damage and edema formation. Evan's Blue staining of the brain parenchyma was absent in healthy Vasp−/− and Vasp+/+ mice as well as sham-operated controls of either genotype suggesting that VASP is of minor importance for the regulation of vascular permeability under basal conditions (not shown). 24h after tMCAO BBB leakage, i.e. Evan's Blue extravasation was more pronounced in Vasp−/− mice compared with littermate controls (39.1 mm3±17.2 mm3 versus 19.5 mm3±7.9 mm3, respectively; p<0.05) (Figure 2C). Accordingly, Vasp−/− mice developed significantly more brain edema (0.8 mm3±0.4 mm3 versus 1.7 mm3±0.5 mm3, respectively; p<0.0001).

Discussion

We here demonstrate that VASP is crucial for maintaining vascular integrity in the ischemic brain. Vasp deficiency resulted in enhanced BBB disruption, edema formation and neuronal damage after experimental stroke in mice.

There is accumulating evidence that VASP is critically involved in stabilizing endothelial barriers. Several studies could demonstrate that VASP co-localizes with cell-cell contacts (e.g. the tight junction marker zonula occludens protein-1) and focal adhesion sites (e.g. VE-cadherin) in endothelial cell cultures [15], [18], [19]. Linkage of intercellular contacts and focal adhesions to the intracellular actin cytoskeleton is important for sufficient sealing [29]. VASP has been shown to regulate actin organization at cadherin-adhesive contacts [30] and stabilize endothelial barrier function by promoting actin polymerization and relaxation of the actin cytoskeleton [18], [19]. Consequently, transendothelial permeability was significantly increased in endothelial cells from Vasp−/− mice [15], [18] and Ena/VASP triple null mice [20].

Most of the data underscoring the significance of VASP for preserving vascular integrity have so far been derived from in vitro studies which in addition were mainly conducted in microvascular endothelial cell lines from myocardium, lung or skin under physiological conditions [15], [16], [19], [28]. We here confirm and further extend these findings by demonstrating that VASP also prevents BBB damage and edema formation in the brain after tMCAO in mice, a well established in vivo model of ischemic stroke. Hypoxemia is a potent trigger of vascular leakage [31][33] and downregulation of VASP by hypoxia-inducible factor (HIF) possibly participates in this process at least in cell culture systems [28]. Because HIF is also strongly induced in the murine brain after tMCAO [34][36], HIF-dependent degradation of VASP could also be functionally relevant for edema formation in ischemic stroke in vivo. Interestingly, inhibition of HIF-1 using small interfering RNA reduced Evan's Blue extravasation and brain ischemia-reperfusion injury in rats [36]. Two recent in vitro studies investigated a possible implication of VASP for hypoxia-induced BBB disruption. Davis and co-workers found that hypoxia-induced VEGF expression increased BBB permeability and correlated with VASP phosphorylation, which was in part mediated through the VEGF receptor 2 [37]. In the second study, the subcellular distribution of VASP in immortalized brain endothelial cells was significantly altered under hypoxic conditions [38].

Inflammation is another well-established trigger of increased vascular permeability [12]. In a model of LPS-induced acute lung injury, Vasp−/− mice showed increased pulmonary damage, neutrophil infiltration and vascular leakage compared with wild-type animals [39]. Benz and co-workers [18] recently reported that Vasp−/− mice develop more skin edema upon subcutaneous injections of the proinflammatory peptide hormone bradykinin, the end product of the kallikrein/kinin-system. In line with these findings, we [40], [41] and others [42] could show that endogenous bradykinin also fosters edema formation in ischemic stroke and traumatic brain injury. However, the exact molecular interplay between the kallikrein/kinin-system and VASP in the context of hypoxia, inflammation and vascular leakage needs to be further established.

Taken together, our study indentifies VASP as critical regulator of BBB maintenance and fluid hemostasis during cerebral ischemia. Interference with VASP or VASP-dependent signalling pathways could become a promising strategy to treat excessive brain edema in stroke and possibly other neurological diseases afflicted with severe BBB disruption.

Materials and Methods

Animals

A total of 89 mice were used in this study. Animal experiments were approved by legal state authorities (Bezirksregierung of Unterfranken, approval number 54-2531.01-25/06) and conducted according to recent recommendations for research in basic stroke studies including blinded evaluation of the results, randomization of animals, predefinition of exclusion criteria, and power calculations (see below) [43]. The generation and extensive characterization of Vasp−/−mice is described elsewhere [44]. 6–8 week old male and female Vasp−/−mice were used and wild-type (WT) littermates (Vasp+/+) matched for age and sex served as controls.

Stroke model

The transient middle cerebral artery occlusion (tMCAO) model was applied to induce focal cerebral ischemia as described elsewhere [45], [46]. Briefly, mice were anesthetized with 2% isoflurane in a 70% N2O/30% O2 mixture. A servo-controlled heating blanket was used to maintain core body temperature close to 37°C throughout surgery. Following a midline neck incision a standardized silicon rubber-coated 6.0 nylon monofilament (60-1720RE; Doccol, Redlands, CA, USA) was inserted into the right common carotid artery and advanced via the internal carotid artery to occlude the origin of the MCA. After 60 min mice were re-anesthetized and the occluding filament was removed to allow reperfusion. Operation time per animal did not exceed 15 min and operators (PK, CK and MA) were blinded for the respective genotypes throughout the study.

The exclusion criteria were as follows:

  1. Death within 24h after tMCAO
  2. Subarachnoid hemorrhage (SAH; as macroscopically assessed during brain sampling)
  3. Bederson score (see below)  = 0 (24 h after tMCAO)

3 out of 43 WT mice (6.9%) and 4 out of 46 Vasp−/− mice (8.7%) met at least one of the exclusion criteria (2 deaths and 1 non-fatal SAH in the WT group and 3 deaths and 1 non-fatal SAH in the Vasp−/− group, respectively). The excluded animals were used only for mortality analysis (Figure 2B). 82 out of 89 mice (92.1%) were included for final analysis.

Anatomical assessment of the cerebral vasculature

For assessment of the cerebral vasculature Vasp-deficient mice and controls (n = 5/group) were deeply anesthetized with CO2 and transcardially perfused with 4% paraformaldehyde (PFA), followed by 3 ml black ink diluted in 4% PFA (1[ratio]5 v/v). Brains were carefully removed, fixed in 4% PFA overnight at 4°C and the Circle of Willis and major arteries were examined under a microscope. To further quantitatively examine the vascular structures, we graded the development of the posterior communicating arteries (PComAs), which can affect brain sensitivity to ischemia [23], according to the following score: 0, absent; 1, capillary anastomosis; 2, small truncal vessel; 3, patent.

Regional cerebral blood flow measurement

Laser-Doppler flowmetry (Moor Instruments, U.K.) was used to monitor regional cerebral blood flow (rCBF) in Vasp−/− mice and WT controls before surgery (baseline), immediately after MCA occlusion, and 10 minutes after removal of the occluding monofilament (reperfusion) (n = 5/group) [47]. For this procedure a small incision was made in the skin overlying the temporal muscle, and a 0.7 mm flexible laser-Doppler probe (model P10) was positioned perpendicular on the superior portion of the temporal bone (6 mm lateral and 2 mm posterior from bregma). This position corresponds to the core of the ischemic territory.

Invasive hemodynamics

For invasive hemodynamics Vasp−/− mice and controls (n = 4/group) were anesthetized with 2.5% isoflurane and catheterized via the right carotid artery with a high-fidelity 1.4 F Millar microtip catheter as described [40]. Hemodynamic data (blood pressure and heart rate) were digitized via a MacLab system (AD Instruments, Castle Hill) connected to an Apple G4 PowerPC computer and analyzed.

Assessment of functional outcome

After recovery from anesthesia and again after 24h, neurological function was assessed by two investigators unaware of the genotype according to the Bederson score (n = 15 in the wild-type and n = 17 in the Vasp−/−group, respectively) [48] with: 0, no deficit; 1, forelimb flexion; 2, as for 1, plus decreased resistance to lateral push; 3, unidirectional circling; 4, longitudinal spinning; 5, no movement. In addition, the mortality rate was monitored until 24h after tMCAO.

Determination of infarct size and edema volumes

Animals were sacrificed 24h after tMCAO. Brains were quickly removed and cut in three 2-mm thick coronal sections using a mouse brain slice matrix (Harvard Apparatus, Holliston, MA, USA). The slices were stained for 20 min at 37°C with 2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich, Taufkirchen, Germany) in PBS to visualize the infarctions [46], [49].

Direct, i.e. without correction for brain edema, and indirect, i.e. corrected for brain edema, infarct volumes (n = 15 in the wild-type and n = 17 in the Vasp−/−group, respectively) were calculated by volumetry (ImageJ software, National Institutes of Health, USA) according to the following equations:

equation image
equation image

where the term An external file that holds a picture, illustration, etc.
Object name is pone.0015106.e003.jpgrepresents the volume difference between the ischemic hemisphere and the control hemisphere and An external file that holds a picture, illustration, etc.
Object name is pone.0015106.e004.jpg expresses this difference as a percentage of the control hemisphere.

Brain edema volumes (n = 15 in the wild-type and n = 17 in the Vasp−/−group, respectively) were then calculated by subtracting indirect from direct infarct volumes.

Determination of blood-brain-barrier leakage

To determine the permeability of the cerebral vasculature 2% Evan's Blue tracer (Sigma Aldrich, Germany) diluted in 0.9% NaCl was i. v. injected 2h after the induction auf tMCAO [40]. After 24h mice (n = 5/group) were transcardially perfused with 4% PFA and brains were quickly removed and cut in 2-mm thick coronal sections using a mouse brain slice matrix (Harvard Apparatus, Holliston, MA, USA). Volumetric measurements (ImageJ software, National Institutes of Health, USA) of the brain parenchyma stained by Evan's Blue were performed to estimate the extent of BBB damage. Sham-operated mice in which the occluding filament was not inserted into the MCA (n = 3/group) and healthy animals (n = 3/group) served as controls.

Statistics

Results are expressed as mean ± standard deviation (SD). For statistical analysis, PrismGraph 4.0 software package (La Jolla, CA, USA) was used. Data were tested for Gaussian distribution with the DAgostino and Pearson omnibus normality test and then analyzed by the unpaired, two-tailed Student's t-test, except for the Bederson score which was analyzed by the non-parametric Mann Whitney test. Mortality rates (Figure 2A) were compared by the Fishe[r with grave]s exact contingency test. For the comparison of regional cerebral blood flow (Figure 1B), Bonferroni-corrected 2-way ANOVA was applied. P-values <0.05 were considered to be statistically significant.

For power and type-II (beta) error calculations on infarct volumes GraphPad Stat Mate 2.0 software package was used (GraphPad Software, Inc, La Jolla, CA, USA): On day 1 after 60 min tMCAO the mean infarct volume was 39.3±10.7 mm3 in Vasp+/+ mice and 56.1±17.3 mm3 in Vasp−/− mice (Figure 2A). We assumed that a reduction or increase in infarct size of ≥35% (Delta  = 13.8 mm3) would be of biological relevance [50], [51]. The significance level (alpha) was chosen as 0.05 (two-tailed). The group size was n = 15 for WT mice and n = 17 for Vasp−/− mice. Given those premises the power to detect a difference of 13.8 mm3 between the mean infarct volumes reached 75% in our study (type-II [beta] error of 25%, respectively) which is a robust result compared to many other experimental stroke studies [43], [52].

Acknowledgments

We thank Melanie Glaser for excellent technical assistance.

Footnotes

Competing Interests: Christoph Kleinschnitz is a PLoS ONE Academic Editor.

Funding: This work was supported by the Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany, SFB 688, TP A2 (to UW), A13 (to CK), and B1 (to GS) and Wilhelm Sander-Stiftung, München, Germany (2009.017.1 to CK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Ayata C, Ropper AH. Ischaemic brain oedema. J Clin Neurosci. 2002;9:113–124. [PubMed]
2. Bardutzky J, Schwab S. Antiedema therapy in ischemic stroke. Stroke. 2007;38:3084–3094. [PubMed]
3. Qizilbash N, Lewington SL, Lopez-Arrieta JM. Corticosteroids for acute ischaemic stroke. Cochrane Database Syst Rev. 2002;2:CD000064. [PubMed]
4. Righetti E, Celani MG, Cantisani T, Sterzi R, Boysen G, et al. Glycerol for acute stroke. Cochrane Database Syst Rev. 2004;2:CD000096. [PubMed]
5. Bereczki D, Fekete I, Prado GF, Liu M. Mannitol for acute stroke. Cochrane Database Syst Rev. 2007;183:CD001153. [PubMed]
6. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6:650–661. [PubMed]
7. Corada M, Mariotti M, Thurston G, Smith K, Kunkel R, et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci USA. 1999;96:9815–9820. [PubMed]
8. Hordijk PL, Anthony E, Mul FP, Rientsma R, Oomen LC, et al. Vascular-endothelial-cadherin modulates endothelial monolayer permeability. J Cell Sci. 1999;112:1915–1923. [PubMed]
9. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004;5:261–270. [PubMed]
10. Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol. 2003;4:225–236. [PubMed]
11. Lai CH, Kuo KH, Leo JM. Critical role of actin in modulating BBB permeability. Brain Res Brain Res Rev. 2005;50:7–13. [PubMed]
12. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006;86:279–367. [PubMed]
13. Mitic LL, Anderson JM. Molecular architecture of tight junctions. Annu Rev Physiol. 1998;60:121–142. [PubMed]
14. Sechi AS, Wehland J. ENA/VASP proteins: multifunctional regulators of actin cytoskeleton dynamics. Front Biosci. 2004;9:1294–1310. [PubMed]
15. Schlegel N, Burger S, Golenhofen N, Walter U, Drenckhahn Dl, et al. The role of VASP in regulation of cAMP- and Rac 1-mediated endothelial barrier stabilization. Am J Physiol Cell Physiol. 2008;294:C178–188. [PubMed]
16. Schlegel N, Waschke J. VASP is involved in cAMP-mediated Rac 1 activation in microvascular endothelial cells. Am J Physiol Cell Physiol. 2009;296:C453–462. [PubMed]
17. Kris AS, Kamm RD, Sieminski AL. VASP involvement in force-mediated adherens junction strengthening. Biochem Biophys Res Commun. 2008;375:134–138. [PMC free article] [PubMed]
18. Benz PM, Blume C, Moebius J, Oschatz C, Schuh K, et al. Cytoskeleton assembly at endothelial cell-cell contacts is regulated by alphaII-spectrin-VASP complexes. J Cell Biol. 2008;180:205–219. [PMC free article] [PubMed]
19. Comerford KM, Lawrence DW, Synnestvedt K, Levi BP, Colgan SP. Role of vasodilator-stimulated phosphoprotein in PKA-induced changes in endothelial junctional permeability. FASEB J. 2002;16:583–585. [PubMed]
20. Furman C, Sieminski AL, Kwiatkowski AV, Rubinson DA, Vasile E, et al. Ena/VASP is required for endothelial barrier function in vivo. J Cell Biol. 2007;179:761–775. [PMC free article] [PubMed]
21. Sporbert AK, Mertsch A, Smolenski RF, Haseloff G, Schonfelder M, et al. Phosphorylation of vasodilator-stimulated phosphoprotein: a consequence of nitric oxide- and cGMP-mediated signal transduction in brain capillary endothelial cells and astrocytes. Brain Res Mol Brain Res. 1999;67:258–266. [PubMed]
22. Barone FC, Knudsen DJ, Nelson AH, Feuerstein GZ, Willette RN. Mouse strain differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy. J Cereb Blood Flow Metab. 1993;13:683–692. [PubMed]
23. Murakami K, Kondo T, Epstein CJ, Chan PH. Overexpression of CuZn-superoxide dismutase reduces hippocampal injury after global ischemia in transgenic mice. Stroke. 1997;28:1797–1804. [PubMed]
24. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav. 2007;87:179–197. [PubMed]
25. Green RA, Odergren T, Ashwood T. Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci. 2003;24:402–408. [PubMed]
26. Yamaguchi T, Suzuki M, Yamamoto M. YM796, a novel muscarinic agonist, improves the impairment of learning behavior in a rat model of chronic focal cerebral ischemia. Brain Res. 1995;669:107–114. [PubMed]
27. Kawamata T, Alexis NE, Dietrich WD, Finklestein SP. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat. J Cereb Blood Flow Metab. 1996;16:542–547. [PubMed]
28. Rosenberger P, Khoury J, Kong T, Weissmüller T, Robinson AM, et al. Identification of vasodilator-stimulated phosphoprotein (VASP) as an HIF-regulated tissue permeability factor during hypoxia. FASEB J. 2007;21:2613–2621. [PubMed]
29. Wu MH. Endothelial focal adhesions and barrier function. J Physiol. 2005;569:359–366. [PubMed]
30. Scott JA, Shewan AM, den Elzen NR, Loureiro JJ, Gertler FB, et al. Ena/VASP proteins can regulate distinct modes of actin organization at cadherin-adhesive contacts. Mol Biol Cell. 2006;17:1085–1095. [PMC free article] [PubMed]
31. Wojciak-Stothard B, Tsang LY, Haworth SG. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2005;288:L749–760. [PubMed]
32. Wojciak-Stothard B, Tsang LY, Paleolog E, Hall SM, Haworth SG. Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;290:L1173–1182. [PubMed]
33. Kayyali US, Pennella CM, Trujillo C, Villa O, Gaestel M, et al. Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2. J Biol Chem. 2002;277:42596–42602. [PubMed]
34. Filiano AJ, Bailey CD, Tucholski J, Gundemir S, Johnson GV. Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. FASEB J. 2008;22:2662–2675. [PubMed]
35. Chen W, Jadhav V, Tang J, Zhang JH. HIF-1alpha inhibition ameliorates neonatal brain injury in a rat pup hypoxic-ischemic model. Neurobiol Dis. 2008;31:433–441. [PMC free article] [PubMed]
36. Chen C, Hu Q, Yan J, Yang X, Shi X, et al. Early inhibition of HIF-1alpha with small interfering RNA reduces ischemic-reperfused brain injury in rats. Neurobiol Dis. 2009;33:509–517. [PubMed]
37. Davis BJ, Tang L, Zhang D, Mu X, Jiang V, et al. Role of vasodilator stimulated phosphoprotein in VEGF induced blood-brain barrier permeability in endothelial cell monolayers. Int J Dev Neurosci. 2010;28:423–428. [PMC free article] [PubMed]
38. Hicks K, O'Neil RG, Dubinsky WS, Brown RC. TRPC-mediated actin-myosin contraction is critical for BBB disruption following hypoxic stress. Am J Physiol Cell Physiol. 2010;298:C1583–1593. [PubMed]
39. Henes J, Schmit MA, Morote-Garcia JC, Mirakaj V, Kohler D, Glover L, et al. Inflammation-associated repression of vasodilator-stimulated phosphoprotein (VASP) reduces alveolar-capillary barrier function during acute lung injury. Faseb J. 2009;23:4244–4255. [PubMed]
40. Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, et al. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke. 2009;40:285–293. [PubMed]
41. Raslan F, Schwarz T, Meuth SG, Austinat M, Bader M, et al. Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J Cereb Blood Flow Metab. 2010;30:1477–1486. [PMC free article] [PubMed]
42. Groeger M, Lebesgue D, Pruneau D, Relton J, Kim SW, et al. Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2005;25:978–989. [PubMed]
43. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab. 2006;26:1465–1478. [PubMed]
44. Hauser W, Knobeloch KP, Eigentaler M, Gambaryan S, Krenn V, et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci USA. 1999;96:8120–8125. [PubMed]
45. Clark WM, Lessov NS, Dixon MP, Eckenstein F. Monofilament intraluminal middle cerebral artery occlusion in the mouse. Neurol Res. 1997;19:641–648. [PubMed]
46. Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, et al. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood. 2010;115:3835–3842. [PubMed]
47. Connolly ES, Jr, Winfree CJ, Stern DM, Solomon RA, Pinsky DJ. Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. Neurosurgery. 1996;38:523–532. [PubMed]
48. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–476. [PubMed]
49. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, et al. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 1986;176:1304–1308. [PubMed]
50. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, et al. 1,026 Experimental treatments in acute stroke. Ann Neurol. 2006;59:467–477. [PubMed]
51. Crossley NA, Sena E, Goehler J, Horn J, van der Worp B, et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke. 2008;39:929–934. [PubMed]
52. Van der Worp HB, de Haan P, Morrema E, Kalkman CJ. Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. J Neurol. 2005;252:1108–1114. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science